EnteroBiotix announces MHRA license approval and strengthened senior management team

ABERDEEN, Scotland–EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare Products Regulatory Agency (MHRA) to further its therapeutic and product pipeline.

EnteroBiotix has also appointed senior biotechnology executive Dr James Clark PhD as CEO, with founder Dr James McIIroy moving to the role of Chief Business Officer in order to support the new CEO and accommodate NHS hospital requirements to complete his medical training as a clinician.

James Clark brings over 20 years of biotechnology and biopharmaceutical drug discovery, development and commercialisation experience to EnteroBiotix. Previous roles have included Chief Technical Officer at Enterome, one of Europe’s leading microbiome companies, and most recently Vice-President of clinical laboratory operations at Inivata, the global clinical cancer genomics group.

Dr James McIlroy, EnteroBiotix founder and Chief Business Officer said: “We are absolutely thrilled to welcome James Clark to the team at this critical inflection point for the business. With the MHRA approval under our belt and a strengthened senior management team, we are well positioned to make an outsized impact in this exciting field of science and medicine. I am grateful to our Board and shareholders for allowing me to continue my NHS medical training alongside my continuing role at EnteroBiotix.”

Dr James Clark PhD, EnteroBiotix CEO, said: “EnteroBiotix is one the most exciting early stage biopharmaceutical startups in the UK, and is attracting significant investor interest. It’s a great time to lead the company and I look forward to working with James and the rest of the team as we enter the next phase of growth.”

About EnteroBiotix

EnteroBiotix is developing novel medicinal products targeting the gut microbiome to serve patients with serious unmet clinical needs. The company has established fully integrated ISO-accredited microbial collection and GMP-compliant processing capabilities under a ‘specials’ license from the MHRA. Headquartered in Aberdeen, EnteroBiotix has to date raised over £2m in equity investment and non-dilutive funding with a dedicated core team supported by an independent Scientific and Medical Advisory Board.

EnteroBiotix unveils major NHS collaboration during visit by Nicola Sturgeon

Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, recently welcomed First Minister Nicola Sturgeon and Scotland’s Chief Medical Officer Catherine Calderwood to its pioneering manufacturing facility and laboratories in Aberdeen as the firm progresses towards commercialisation of its products.

EnteroBiotix founder & CEO Dr James McIIroy shows the First Minister Nicola Sturgeon around the EnteroBiotix facilities

Founded in 2017 by recently qualified doctor at the University of Aberdeen, 25-year old Dr James McIlroy, EnteroBiotix develops faecal derived products for patients suffering from diseases associated with bacterial imbalances in the intestinal gut.

The Company’s novel medicinal products build on the clinically proven strategy of faecal microbiota transplantation (FMT). FMT is the process of transferring bacteria from the gut of a healthy donor into the gut of a recipient to restore a healthy balance.

On the occasion of the First Minister’s visit, EnteroBiotix announced a pioneering collaboration with the Academic Health Science Partnership in Tayside and National Health Service to accelerate and catalyse the adoption of its product line by NHS Tayside.

The collaboration will involve clinical studies, a health economic analysis and the development of a business case for use of EnteroBiotix’s advanced products.

EnteroBiotix founder and CEO, Dr. James McIlroy, said: “The facilities and resources now available to us are game-changing for the company and our product pipeline.

“We now have a platform to develop products for patient use and clinical trials and our collaboration with NHS Tayside and the Academic Health Science Partnership gives us an enormous advantage moving forward as we look to establish ourselves as one of the main players in the fast-moving and exciting field of the microbiome.”

First Minister for Scotland, Nicola Sturgeon, said: “Scotland has a thriving life sciences sector that is renowned globally for innovation and its contribution to pioneering treatments for patients with serious medical conditions.

“Scottish companies like EnteroBiotix are testament to this. The research undertaken at this new facility will have a massive impact on future medical treatments for patients both here in Scotland and further afield.

The Scottish Government recognises the importance of creating the right environment to allow innovative companies, such as EnteroBiotix, to prosper and I’m pleased the Scottish Government, through Scottish Enterprise, has provided the support for them to grow.”

Chief Medical Officer for Scotland, Catherine Calderwood, said: “It is vital that new clinical treatments are developed to meet patient needs and EnteroBiotix is a good example of this. I welcome the announcement of their new partnership with NHS Tayside which will help progress this important research further.”

About EnteroBiotix

EnteroBiotix is a patient-centred biotechnology company developing novel medicinal products for use in infections or diseases associated with imbalances of bacteria in the human gut. The Company has established, staffed and integrated an ISO-accredited controlled donation facility and a fully equipped state-of-the-art manufacturing facility to manage the collection, processing and formulation of medicinal products derived from healthy human donations. Headquartered in Aberdeen, EnteroBiotix has raised £700,000 in equity investment and non-dilutive funding with a dedicated core team of seven supported an Independent Scientific and Medical Advisory Board.

For further information, please contact:

Dr. James McIlroy, CEO

info@enterobiotix.com

EnteroBiotix celebrates success at UK emerging entrepreneur of the year awards

Aberdeen, Scotland – EnteroBiotix, a privately held Scottish biotechnology company focused on using the body’s own microorganisms to prevent and treat disease, today announced that the Company’s CEO, James McIlroy, was awarded the title of ‘Emerging Entrepreneur of the Year’ at the 2017 BQ National Entrepreneur Festival.

Hosted by BQ and powered by Atom Bank, the awards brought together entrepreneurs from across the UK with the challenge of identifying individuals who, in the view of the judges, are part of the next generation of successful entrepreneurs.

The Scottish award was supported by Scottish Institute for Enterprise. CEO Fiona Godsman said:

“Scotland’s historic contribution to innovation both in the UK and the wider world is widely known. We’re very proud of the next generation of Scottish innovators at SIE and we’re very pleased to help showcase some of our brightest new talent on the national stage. The Scottish winner, James McIlroy, is an excellent example of someone using entrepreneurship to solve a real problem. He’s made great strides with EnteroBiotix which has already gained significant traction and investment”

For further information, please see the official article on the BQ Website.

About EnteroBiotix

EnteroBiotix is a patient-centred biotechnology company developing novel medicinal products for use in infections or diseases associated with imbalances of bacteria in the human gut. The Company has established, staffed and integrated an ISO-accredited controlled donation facility and a fully equipped state-of-the-art manufacturing facility to manage collection, processing and formulation of medicinal products derived from healthy human donations. Headquartered in Aberdeen, EnteroBiotix has raised £700,000 in equity investment and non-dilutive funding with a dedicated core team of seven supported an Independent Scientific and Medical Advisory Board.

For further information, please contact:

James McIlroy, CEO

info@enterobiotix.com

 www.enterobiotix.com